Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer.

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/43048

Title:	Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer.
Authors:	Melisi, Davide García-Carbonero, Rocío Macarulla, Teresa Pezet, Denis Deplanque, Gael Fuchs, Martin Trojan, Jorg Oettle, Helmut Kozloff, Mark Cleverly, Ann Smith, Claire Estrem, Shawn T Gueorguieva, Ivelina Lahn, Michael M F Blunt, Al Benhadji, Karim A Tabernero, Josep View more
Issue Date:	2018
Citation:	Br. J. Cancer.2018 11;(119)10:1208-1214
Abstract:	Galunisertib is the first-in-class, first-in-human, oral small-molecule type I transforming growth factor-beta receptor (ALK5) serine/threonine kinase inhibitor to enter clinical development. The effect of galunisertib vs. placebo in patients with unresectable pancreatic cancer was determined.
PMID:	30318515
URI:	https://hdl.handle.net/20.500.12530/43048
Rights:	openAccess
Appears in Collections:	Hospitales > H. U. 12 de Octubre > Artículos Fundaciones e Institutos de Investigación > IIS H. U. 12 de Octubre > Artículos

Files in This Item:

File	Description	Size	Format
PMC6251034.pdf		1.34 MB	Adobe PDF	View/Open